Type 1 diabetes is caused by the immune system attacking and destroying the insulin-producing cells in the pancreas. About 1.8 million people in the U.S. have this condition, and unlike type 2 diabetes, it has nothing to do with diet or lifestyle. The destruction is driven by a combination of genetic susceptibility and environmental triggers that, together, set off an immune response the body can’t shut down.
How the Immune System Destroys Insulin-Producing Cells
The pancreas contains clusters of cells called islets, and within those islets are beta cells, which are the only cells in the body that produce insulin. In type 1 diabetes, the immune system mistakes these beta cells for a threat and sends waves of immune cells to destroy them.
The attack starts with a specific type of white blood cell called a T helper cell (CD4 T cell). These cells travel to the pancreas and release inflammatory signals, including proteins that are directly toxic to beta cells. Those same signals activate another class of immune cells called macrophages, which amplify the damage by producing additional inflammatory molecules. As this inflammation builds, a second wave of immune cells (CD8 T cells, sometimes called “killer” T cells) infiltrate the islets and destroy beta cells through direct contact, punching holes in them with specialized proteins.
The body does attempt to fight back. Regulatory T cells try to calm the immune response by releasing anti-inflammatory signals. But in people who develop type 1 diabetes, this braking mechanism isn’t strong enough. The destruction continues until roughly 80 to 90 percent of beta cells are gone, at which point the body can no longer produce enough insulin to regulate blood sugar, and symptoms appear.
The Role of Genetics
Type 1 diabetes runs in families, but not in a straightforward way. Most people who develop it have no close relatives with the condition. What they do carry are specific gene variants in a region of the genome responsible for helping the immune system distinguish the body’s own cells from foreign invaders. Certain combinations of these gene variants dramatically increase risk, with one particular high-risk combination raising the odds by roughly 90 times compared to the general population.
More than 60 different genetic regions have been linked to type 1 diabetes risk, but the immune-system genes account for roughly half the inherited susceptibility. The rest involve genes that influence how T cells develop, how the immune system is regulated, and how beta cells respond to stress.
Risk From a Parent With Type 1 Diabetes
If one of your parents has type 1 diabetes, your risk is higher than the general population’s but still relatively low. By age 20, roughly 4 to 5 percent of children born to a parent with type 1 diabetes develop it themselves. Older data suggested the risk was notably higher when the father had type 1 versus the mother, but more recent research with longer follow-up shows the difference is smaller than originally thought. Boys appear to face slightly higher risk than girls: in one study, 6.9 percent of sons born to mothers with early-onset type 1 developed the condition by age 20, compared to 2.7 percent of daughters.
Environmental Triggers
Genes load the gun, but something in the environment pulls the trigger. Researchers have identified several factors that appear to initiate or accelerate the autoimmune process in genetically susceptible people.
Viral Infections
Certain viruses, particularly a group called coxsackieviruses, have the strongest link to type 1 diabetes onset. These viruses can infect beta cells directly, killing some and damaging others. But the more important effect may be what happens next: as the immune system mounts a response against the virus, it can accidentally begin targeting beta cells too. One proposed explanation is molecular mimicry, where proteins on the virus’s surface closely resemble proteins on beta cells, confusing the immune system into attacking both. In some cases, the viral infection may simply cause enough beta cell damage to expose hidden cell components to the immune system, kick-starting an autoimmune response in someone whose genetics made that response possible.
Vitamin D and Early-Life Exposures
Low vitamin D levels in infancy and childhood have been associated with a higher risk of developing type 1 diabetes, though the evidence is mixed. One large follow-up study found that children with adequate vitamin D levels had about 40 percent lower odds of developing the autoimmune markers that precede type 1 diabetes compared to children with low levels. Several case-control studies have found that children with notably low vitamin D face anywhere from 1.4 to nearly 6 times the risk. However, two other studies that measured vitamin D from newborn blood samples found no significant association, suggesting the timing and duration of deficiency may matter more than a single measurement at birth.
The Gut Microbiome
The composition of bacteria in the gut plays a surprisingly important role in training the immune system during early life. Research in animal models has shown that specific gut bacteria can influence whether autoimmune diabetes develops, with certain bacterial strains offering protection and a less diverse microbiome increasing vulnerability. One particular type of gut bacteria, segmented filamentous bacteria, has been shown to drive the development of specific immune cells that influence the balance between immune tolerance and autoimmunity. The broader idea, sometimes called the hygiene hypothesis, suggests that reduced exposure to diverse microbes in early childhood (through increased sanitation, antibiotic use, and less time outdoors) may leave the immune system poorly calibrated and more prone to attacking the body’s own tissues. This could partly explain why type 1 diabetes rates have been rising steadily in developed countries.
The Three Stages Before Symptoms Appear
Type 1 diabetes doesn’t happen overnight. The autoimmune process unfolds over months or years, and researchers now classify it into three distinct stages. Understanding these stages matters because it’s now possible to detect the disease before symptoms ever appear through blood tests that look for autoantibodies, immune proteins that signal the attack on beta cells has begun.
In stage 1, a person has two or more of these autoantibodies in their blood, but their blood sugar is completely normal and they feel fine. In stage 2, the autoantibodies are still present and blood sugar is starting to become abnormal, though not yet high enough to be diagnosed as diabetes. There are still no symptoms. Stage 3 is clinical diabetes, where blood sugar is persistently elevated and symptoms like excessive thirst, frequent urination, weight loss, and fatigue typically appear. Some people, especially young children, are first diagnosed during a dangerous complication called diabetic ketoacidosis, which is why early screening in high-risk families is increasingly recommended.
The lifetime risk of progressing from stage 1 to stage 3 is very high. Most people with two or more autoantibodies will eventually develop clinical diabetes, though the timeline varies from months to decades.
A New Option to Delay Onset
For the first time, there is an FDA-approved treatment that can delay the progression from stage 2 to stage 3 type 1 diabetes. In a clinical trial, people who received this immune-modulating therapy (teplizumab) took a median of about 4 years to develop clinical diabetes, compared to roughly 2 years in the group that received a placebo. In an extended follow-up averaging over 6 years, the treated group’s median time to diagnosis stretched to nearly 5 years. The treatment works by dampening the specific immune cells responsible for beta cell destruction, essentially slowing the autoimmune process. The greatest benefit appeared in the first year after treatment.
This doesn’t prevent type 1 diabetes, but an extra two to three years without the disease is meaningful, particularly for children and adolescents. It represents a fundamental shift in how the condition is approached: rather than waiting for symptoms and then managing blood sugar for life, it’s now possible to intervene during the silent autoimmune phase.
Who Gets Type 1 Diabetes
Type 1 diabetes affects roughly 4 in every 1,000 children and 5 in every 1,000 adults in the U.S. It’s often called “juvenile diabetes,” but that label is misleading. While it’s commonly diagnosed in childhood and adolescence, with the highest rates among kids aged 10 to 17, the peak adult prevalence is actually in the 45 to 64 age group. Adults can and do develop type 1 diabetes, and it’s frequently misdiagnosed as type 2 in people over 30.
Among children, rates are highest in non-Hispanic White youth and boys. Among adults, non-Hispanic White adults have the highest prevalence at roughly 6 per 1,000, followed by non-Hispanic Black adults at about 5 per 1,000. These demographic patterns likely reflect differences in the genetic variants that drive susceptibility, combined with environmental exposures that vary across populations.